Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an update.
Chimeric Therapeutics has announced a proposed issue of up to 313,291 ordinary fully paid shares, to be conducted as a placement or similar type of securities issue on the ASX. The new shares are expected to be issued on May 11, 2026, which will modestly increase the company’s share capital and may provide additional funding flexibility for its ongoing operations and development activities.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd is an Australian biotechnology company listed on the ASX, focused on developing innovative therapeutic products. The company operates in the biopharmaceutical sector, with its ordinary fully paid shares traded under the ticker CHM.
Average Trading Volume: 244,299
Technical Sentiment Signal: Sell
Current Market Cap: A$7.77M
For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.